Navigation Links
Cephalon to Webcast Investor Day
Date:11/12/2010

ments provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion. Investor contacts:Robert (Chip) Merritt610-738-6376cmerritt@cephalon.comJoseph Marczely610-883-5894jmarczely@cephalon.com
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
2. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
3. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
4. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
5. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
6. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
7. Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position
8. Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
9. Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
10. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
11. Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 5, 2015  IRIDEX Corporation (Nasdaq: IRIX ) ... ended January 3, 2015.  , Revenues were $11.8 ... the Company and up 11% from $10.6 million in the ... a record, up 12% from $38.3 million in 2013. ... up from 48.6% in the fourth quarter of the prior ...
(Date:3/5/2015)... 5, 2015  As the pharmaceutical industry works ... & Compliance professionals are placing a significant emphasis ... issued today by LRN, the leader in Ethics ... majority of respondents expressed that clarity on company ... of E&C training programs (57%), trumping understanding of ...
(Date:3/5/2015)... FALLS, N.J. , March 5, 2015 CANTEL ... results for its second quarter ended January 31, 2015 on ... conference call to discuss the results at 11:00 AM ET. ... (877) 407-8033 approximately 5 to 10 minutes before the beginning ... digital replay of the call will be available from Thursday, ...
Breaking Medicine Technology:IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... tumors (NET) experienced,clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR ... Depot, - 77% of patients with pancreatic NET ... treated with daily RAD001, - Data show RAD001, an ... have limited ...
... Sept. 12 InVitria,( http://www.InVitria.com ), a ... enhance productivity, safety and time to market ... science research and,diagnostics industry, will be an ... and Exhibition in Anaheim, California on September,23-26. ...
Cached Medicine Technology:RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 2RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 3RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 4RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 5RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 6RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 7InVitria Showcases Cell Culture Productivity Enhancers at BioProcess International 2
(Date:3/6/2015)... California (PRWEB) March 06, 2015 ... one of the most common forms of cancer and ... Breast cancer can be screened through various techniques and ... Mammography however remains the gold standard technique in breast ... as cost, time taken for the procedure, required expertise ...
(Date:3/6/2015)... York, NY (PRWEB) March 06, 2015 Ticket ... tickets . This popular ticket exchange has extended their customer ... hails from Hebden Bridge, West Yorkshire England and he began ... 2005. In the past couple of years Ed Sheeran ... though whenever Ed Sheeran is on stage he is having ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Further solidifying ... , Medical Doctor Associates announced today that the company ... after winning the Best of Staffing Talent Award five ... Inavero’s Best of Staffing Talent Diamond winners are proven ... given to them by the individuals they have helped ...
(Date:3/6/2015)... TN (PRWEB) March 06, 2015 Since ... January 1, 2015, there has been an overwhelming demand ... an efficient and compliant CCM program. The Centers ... on several matters. , PYA’s updated white paper—“ ... this new guidance into a detailed, yet practical “how ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Magellan Rx ... only comprehensive source for key trends and statistics on ... medical injectables. Executives from Magellan Rx Management will discuss ... Report: Discover Your Hidden Specialty Drug Spend,” a complimentary ... Services, Inc. , Specialty drug spend makes up more ...
Breaking Medicine News(10 mins):Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Ed Sheeran Tickets in Indianapolis, Austin, Albany, St. Louis, London, Des Moines, Salt Lake City, Saskatoon, Regina and Denver/Morrison Now On Sale at Ticket Down 2Health News:Cross Country Healthcare: Medical Doctor Associates Earns Inavero's 2015 Best of Staffing Talent Diamond Award 2Health News:Cross Country Healthcare: Medical Doctor Associates Earns Inavero's 2015 Best of Staffing Talent Diamond Award 3Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2
... available in German . , Scientists from the ... lived off more than 100 million years ago. They want to ... as they did. In actual fact such gigantic animals should not ... in the journal ,Proceedings of the Royal Society B,. , Take ...
... & Melinda Gates Foundation to ... in 11 new countries, OAK BROOK, Ill., Feb. 6 ... it has received a $24.2 million grant from the Bill ... Micro Insurance Agency, greatly expand its insurance,products to the poor ...
... allayed some panic about suspected cancer-causing agents, such as ... has been developed through the Cancer Control Program at ... University of New South Wales (UNSW) researcher, Professor Bernard ... level of risk is high say, on a ...
... Feb. 6 Parental Alienation Awareness,Organization (PAAO) is beginning ... for April 25th - Parental Alienation Awareness Day., ... until they,experience it, parental alienation awareness was put forth ... The mission of PAAO is to help the ...
... PALO ALTO, Calif., Feb. 6 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... fourth quarter and full year 2007 financial results on ... financial markets. Jazz,Pharmaceuticals will host an investor conference call ... updates on February 13, 2008, at,5:00 p.m. Eastern Time/2:00 ...
... The Female Health Company,(Amex: FHC ) today announced ... the Premarket Approval Application (PMA) it submitted for,its second ... The Center for Devices and Radiological Health (CDRH) received,FHC,s ... Health Company, Inc., The Female Health Company, based ...
Cached Medicine News:Health News:Bonn scientists simulate dinosaur digestion in the lab 2Health News:Bonn scientists simulate dinosaur digestion in the lab 3Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 2Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 3Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 4Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 5Health News:Reducing cancer panic 2Health News:Parental Alienation Awareness Organization Begins Preparations for Parental Alienation Awareness Day - April 25th 2Health News:Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008 2Health News:The Female Health Company Announces FDA Acceptance for Review of Its FC2 Premarket Approval Application 2
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
... The Identity pacemaker family, which ... pacemaker, provides clinicians with the ... including the revolutionary AF Suppression™ ... U.S. commercially approved algorithm designed ...
Innovative new tools for more efficient patient management begin when the pacemaker is implanted. These sophisticated tools are in effect each day, and they help automate follow-up tasks....
The INSIGNIA® pacing systems allow the physician to provide customized adaptive-rate pacing therapy to meet individual patient needs....
Medicine Products: